Beauty Health (NASDAQ:SKIN – Get Free Report) and Boston Scientific (NYSE:BSX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.
Insider and Institutional Ownership
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by insiders. Comparatively, 0.5% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Beauty Health has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beauty Health | 3 | 7 | 1 | 0 | 1.82 |
| Boston Scientific | 0 | 3 | 19 | 1 | 2.91 |
Beauty Health presently has a consensus price target of $2.46, indicating a potential upside of 51.75%. Boston Scientific has a consensus price target of $93.39, indicating a potential upside of 5.11%. Given Beauty Health’s higher probable upside, research analysts plainly believe Beauty Health is more favorable than Boston Scientific.
Profitability
This table compares Beauty Health and Boston Scientific’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beauty Health | -22.86% | -4.57% | -0.37% |
| Boston Scientific | 11.26% | 17.23% | 9.52% |
Earnings and Valuation
This table compares Beauty Health and Boston Scientific”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beauty Health | $398.00 million | 0.50 | -$100.12 million | ($0.83) | -1.95 |
| Boston Scientific | $14.24 billion | 9.20 | $1.59 billion | $1.21 | 73.43 |
Boston Scientific has higher revenue and earnings than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Summary
Boston Scientific beats Beauty Health on 11 of the 15 factors compared between the two stocks.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
